Abstract
Sorbitol dehydrogenase (SDH) is the second enzyme in the polyol pathway of glucose metabolism and is a possible target for the treatment of the complications of diabetes. In this study the molecular modelling program DOCK was used to analyse 249,071 compounds from the National Cancer Institute Database and predict those with high affinity for SDH. From a total of 21 tested the 7 compounds including flavin adenine dinucleotide disodium hydrate, (+)- Amethopterin, 3-hydroxy-2-napthoic(2-hydroxybenzylidene) hydrazide, folic acid, N-2,4-dinitrophenyl-L-cysteic acid, Vanillin azine and 1H-indole-2,3-dione,5-bromo-6-nitro-1-(2,3,4-tri-O-acetyl-α-L-arabinopyranosyl)-(9Cl), were shown to inhibit SDH and displayed IC50 values of 0.192 μM, 1.1 μM, 1.2 μM, 4.5 μM, 5.3 μM, 7 μM and 28 μM, respectively. These compounds may aid the design of pharmaceutical agents for the treatment of diabetes complications.
Keywords: SDH inhibitor, Zn atom, NCI database, spectrophotometer, DOCK program
Medicinal Chemistry
Title: Discovery of Potential Sorbitol Dehydrogenase Inhibitors from Virtual Screening
Volume: 2 Issue: 3
Author(s): Ossama El-Kabbani, Deborah A. Carper, Takeshi Iwata and Connie Darmanin
Affiliation:
Keywords: SDH inhibitor, Zn atom, NCI database, spectrophotometer, DOCK program
Abstract: Sorbitol dehydrogenase (SDH) is the second enzyme in the polyol pathway of glucose metabolism and is a possible target for the treatment of the complications of diabetes. In this study the molecular modelling program DOCK was used to analyse 249,071 compounds from the National Cancer Institute Database and predict those with high affinity for SDH. From a total of 21 tested the 7 compounds including flavin adenine dinucleotide disodium hydrate, (+)- Amethopterin, 3-hydroxy-2-napthoic(2-hydroxybenzylidene) hydrazide, folic acid, N-2,4-dinitrophenyl-L-cysteic acid, Vanillin azine and 1H-indole-2,3-dione,5-bromo-6-nitro-1-(2,3,4-tri-O-acetyl-α-L-arabinopyranosyl)-(9Cl), were shown to inhibit SDH and displayed IC50 values of 0.192 μM, 1.1 μM, 1.2 μM, 4.5 μM, 5.3 μM, 7 μM and 28 μM, respectively. These compounds may aid the design of pharmaceutical agents for the treatment of diabetes complications.
Export Options
About this article
Cite this article as:
El-Kabbani Ossama, Carper A. Deborah, Iwata Takeshi and Darmanin Connie, Discovery of Potential Sorbitol Dehydrogenase Inhibitors from Virtual Screening, Medicinal Chemistry 2006; 2 (3) . https://dx.doi.org/10.2174/157340606776930772
DOI https://dx.doi.org/10.2174/157340606776930772 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuron-Microglia Interactions in Motor Neuron Degeneration. The Inflammatory Hypothesis in Amyotrophic Lateral Sclerosis Revisited
Current Medicinal Chemistry The Future of Neuroregenerative Therapy for Parkinson’s Disease
Current Tissue Engineering (Discontinued) Oxidative Stress and Altered Mitochondrial Function in Neurodegenerative Diseases: Lessons From Mouse Models
CNS & Neurological Disorders - Drug Targets Neuroprotection and Regeneration Strategies for Spinal Cord Repair
Current Pharmaceutical Design Neuroprotective Effects of Low-dose Lithium in Individuals at Ultra-high Risk for Psychosis. A Longitudinal MRI/MRS Study
Current Pharmaceutical Design Inflammatory Process as a Determinant Factor for the Degeneration of Substantia Nigra Dopaminergic Neurons: Possible Relevance to the Etiology of Parkinsons Disease
Current Medicinal Chemistry - Central Nervous System Agents Antioxidants in the Practice of Medicine; What Should the Clinician Know?
Cardiovascular & Hematological Disorders-Drug Targets Hybrid-Based Multi-Target Ligands for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry The Emerging Roles of Leptin and Ghrelin in Cardiovascular Physiology and Pathophysiology
Current Vascular Pharmacology Agave (Agave spp.) and its Traditional Products as a Source of Bioactive Compounds
Current Bioactive Compounds Recommendations for the Treatment of Hypertension in Patients with DM: Critical Evaluation Based on Clinical Trials
Current Clinical Pharmacology Epigenetic control of cardiovascular health by nutritional polyphenols involves multiple chromatin-modifying writer-reader-eraser proteins
Current Topics in Medicinal Chemistry Novel Somatic Mutations of the CDH1 Gene Associated with Gastric Cancer: Prediction of Pathogenicity Using Comprehensive In silico Methods
Current Pharmacogenomics and Personalized Medicine Induced Adaptive Resistance to Nitrooxidative Stress in the CNS: Therapeutic Implications
Central Nervous System Agents in Medicinal Chemistry Editorial (Thematic Issue: Natural Polyphenols and Diabetes: Understanding their Mechanism of Action)
Current Medicinal Chemistry MiR-106a Associated with Diabetic Peripheral Neuropathy Through the Regulation of 12/15-LOX-meidiated Oxidative/Nitrative Stress
Current Neurovascular Research Status of Herbal Medicines in the Treatment of Diabetes: A Review
Current Diabetes Reviews Bis(thiosemicarbazone) Metal Complexes as Therapeutics for Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Improving Antihypertensive Agent Selection to Promote Nephroprotection
Current Hypertension Reviews Cerebrovascular Complications of Diabetes: Focus on Stroke
Endocrine, Metabolic & Immune Disorders - Drug Targets